Nuala Moran
- Feature
Transparency measures forced on pharma
Previous misdemeanours are compelling the pharmaceutical industry to be more open with financial information and clinical data, writes Nuala Moran
- Feature
The hunt for innovation
Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom
- News
Threat to Israeli participation in EU science programme
Rule change means that EU funding cannot go to institutions in occupied territories amid warnings all scientific cooperation could cease
- Feature
Phasing out fire retardants
With many brominated flame retardants facing bans, Nuala Moran examines the industry’s dash for new ones
- Feature
Changing the rules of extraction
As the price of oil goes up, reserves previously uneconomical to exploit become attractive. Nuala Moran explores the chemical technology being used
- Business
Single EU patent agreed for 2014
European commission says long awaited single patent will cut cost of filing by 87%
- Business
Can the UK fund CCS?
EU is offering €1.5 billion in funding but lack of co-ordination with UK scheme threatens participation
- Business
Low salt diet to flush out oil
Better understanding of oil–clay chemistry could increase the world’s recoverable oil by billions of barrels
- News
Plan to tackle EU funding disparity
Pilot project will use infrastructure cash to create ‘pockets of excellence’ in eastern Europe
- News
Europe-wide single patent stalls again
Row over ultimate control of the planned European single patent court brings the process to a juddering halt once more
- News
Campaigners win fight to reform English libel laws
New bill will protect scientists and journalists from vexatious suits when highlighting concerns with scientific evidence
- News
World's first therapeutic cancer vaccine approved
US biotech Antigenics wins Russian approval to market kidney cancer treatment
- Feature
The chemistry of private equity
Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? Nuala Moran reports